Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maternal RSV Vaccination and Infant Nirsevimab Immunization During the First Year of Life
NCT06551506Phase 4Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2024
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Vaccines & Immunotherapeutics, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 4 trial of RSVpreF vaccine, nirsevimab in respiratory syncytial virus infection (RSV), sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2024; status: completed.
02
Drugs
RSVpreF vaccinenirsevimab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06551506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06551506.